192 related articles for article (PubMed ID: 37831273)
1. CR5/CCL5 axis is linked to a poor outcome, and inhibition reduces metastasis in oral squamous cell carcinoma.
González-Arriagada WA; Coletta RD; Lozano-Burgos C; García C; Maripillán J; Alcayaga-Miranda F; Godínez-Pacheco B; Oyarce-Pezoa S; Martínez-Flores R; García IE
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17335-17346. PubMed ID: 37831273
[TBL] [Abstract][Full Text] [Related]
2. CCR5-Mediated Signaling Is Involved in Invasion of Glioblastoma Cells in Its Microenvironment.
Novak M; Koprivnikar Krajnc M; Hrastar B; Breznik B; Majc B; Mlinar M; Rotter A; Porčnik A; Mlakar J; Stare K; Pestell RG; Lah Turnšek T
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545571
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma.
Dunbar KJ; Karakasheva TA; Tang Q; Efe G; Lin EW; Harris M; Sahu V; Sachdeva UM; Hu J; Klein-Szanto AJ; Henick B; Diehl JA; Nakagawa H; Rustgi AK
Mol Cancer Res; 2023 Jul; 21(7):741-752. PubMed ID: 37027010
[TBL] [Abstract][Full Text] [Related]
4. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.
Casagrande N; Borghese C; Visser L; Mongiat M; Colombatti A; Aldinucci D
Haematologica; 2019 Mar; 104(3):564-575. PubMed ID: 30309853
[TBL] [Abstract][Full Text] [Related]
5. The CCL5/CCR5 Axis Promotes Vascular Smooth Muscle Cell Proliferation and Atherogenic Phenotype Switching.
Lin CS; Hsieh PS; Hwang LL; Lee YH; Tsai SH; Tu YC; Hung YW; Liu CC; Chuang YP; Liao MT; Chien S; Tsai MC
Cell Physiol Biochem; 2018; 47(2):707-720. PubMed ID: 29794461
[TBL] [Abstract][Full Text] [Related]
6. Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro.
Wu YC; Shen YC; Chang JW; Hsieh JJ; Chu Y; Wang CH
Cytokine; 2018 Oct; 110():94-103. PubMed ID: 29705397
[TBL] [Abstract][Full Text] [Related]
7. Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy.
Nie Y; Huang H; Guo M; Chen J; Wu W; Li W; Xu X; Lin X; Fu W; Yao Y; Zheng F; Luo ML; Saw PE; Yao H; Song E; Hu H
Clin Cancer Res; 2019 Jul; 25(13):3873-3886. PubMed ID: 30890553
[TBL] [Abstract][Full Text] [Related]
8. Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis.
Pervaiz A; Zepp M; Georges R; Bergmann F; Mahmood S; Faiza S; Berger MR; Adwan H
J Cancer Res Clin Oncol; 2021 Jan; 147(1):73-91. PubMed ID: 32902795
[TBL] [Abstract][Full Text] [Related]
9. A novel antagonist of the CCL5/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation.
Chen L; Xu G; Song X; Zhang L; Chen C; Xiang G; Wang S; Zhang Z; Wu F; Yang X; Zhang L; Ma X; Yu J
Cancer Lett; 2024 Feb; 583():216635. PubMed ID: 38237887
[TBL] [Abstract][Full Text] [Related]
10. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
Wang SW; Liu SC; Sun HL; Huang TY; Chan CH; Yang CY; Yeh HI; Huang YL; Chou WY; Lin YM; Tang CH
Carcinogenesis; 2015 Jan; 36(1):104-14. PubMed ID: 25330803
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
Jin K; Pandey NB; Popel AS
Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
[TBL] [Abstract][Full Text] [Related]
12. CCR5 antagonist treatment inhibits vascular injury by regulating NADPH oxidase 1.
Singh S; Bruder-Nascimento A; Belin de Chantemele EJ; Bruder-Nascimento T
Biochem Pharmacol; 2022 Jan; 195():114859. PubMed ID: 34843718
[TBL] [Abstract][Full Text] [Related]
13. The CCL5/CCR5 axis contributes to the perineural invasion of human salivary adenoid cystic carcinoma.
Shen Z; Li T; Chen D; Jia S; Yang X; Liang L; Chai J; Cheng X; Yang X; Sun M
Oncol Rep; 2014 Feb; 31(2):800-6. PubMed ID: 24337063
[TBL] [Abstract][Full Text] [Related]
14. The CCL5/CCR5 Axis in Cancer Progression.
Aldinucci D; Borghese C; Casagrande N
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630699
[TBL] [Abstract][Full Text] [Related]
15. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells.
Singh SK; Mishra MK; Eltoum IA; Bae S; Lillard JW; Singh R
Sci Rep; 2018 Jan; 8(1):1323. PubMed ID: 29358632
[TBL] [Abstract][Full Text] [Related]
16. CCL5 derived from platelets increases megakaryocyte proplatelet formation.
Machlus KR; Johnson KE; Kulenthirarajan R; Forward JA; Tippy MD; Soussou TS; El-Husayni SH; Wu SK; Wang S; Watnick RS; Italiano JE; Battinelli EM
Blood; 2016 Feb; 127(7):921-6. PubMed ID: 26647394
[TBL] [Abstract][Full Text] [Related]
17. Biological and Clinical Significance of the CCR5/CCL5 Axis in Hepatocellular Carcinoma.
Singh SK; Mishra MK; Rivers BM; Gordetsky JB; Bae S; Singh R
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260550
[TBL] [Abstract][Full Text] [Related]
18. The potential to target CCL5/CCR5 in breast cancer.
Velasco-Velázquez M; Xolalpa W; Pestell RG
Expert Opin Ther Targets; 2014 Nov; 18(11):1265-75. PubMed ID: 25256399
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.
Aldinucci D; Casagrande N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772686
[TBL] [Abstract][Full Text] [Related]
20. Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme.
Kranjc MK; Novak M; Pestell RG; Lah TT
Radiol Oncol; 2019 Nov; 53(4):397-406. PubMed ID: 31747383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
